General Catalyst Group Management’s Eikon Therapeutics EIKN Stock Holding History

General Catalyst Group Management’s Portfolio EIKN Stock Details EIKN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.23M	Buy	+305,233	New	+$4.08M	1.76%	6

Other funds holding EIKN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

General Catalyst Group Management's EIKN Position: Q1 2026 in Review

General Catalyst Group Management opened a new position in Eikon Therapeutics (EIKN) in Q1 2026: 305,233 shares worth $3.23M. The stake represents 1.76% of the portfolio and ranks #6 among its holdings.

52 funds tracked by Wall St. Rank hold EIKN as of Q1 2026.

General Catalyst Group Management held 305,233 shares of Eikon Therapeutics worth $3.23M as of Q1 2026.
Eikon Therapeutics was a new General Catalyst Group Management position in Q1 2026.
Eikon Therapeutics made up 1.76% of General Catalyst Group Management's portfolio in Q1 2026, its #6 holding.
52 funds tracked by Wall St. Rank held Eikon Therapeutics as of Q1 2026.

Based on General Catalyst Group Management's 13F filing for Q1 2026, filed 15 May 2026.